Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study

BACKGROUND: Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Yuzo, Mori, Kazutaka, Aono, Yuya, Kono, Masato, Hasegawa, Hirotsugu, Yokomura, Koshi, Naoi, Hyogo, Hozumi, Hironao, Karayama, Masato, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Inui, Naoki, Nakamura, Hidenori, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274040/
https://www.ncbi.nlm.nih.gov/pubmed/34247593
http://dx.doi.org/10.1186/s12890-021-01587-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274040/
https://www.ncbi.nlm.nih.gov/pubmed/34247593
http://dx.doi.org/10.1186/s12890-021-01587-3

Ejemplares similares